Day: May 1, 2022

Trondheim, 1 May 2022: Reference is made to the stock exchange notice dated 1 March 2022, where NORBIT announced to be in exclusive negotiations regarding a minor add-on acquisition of an undisclosed international maritime technology company. Completion of the transaction was subject to a number of conditions, of which some were not fulfilled satisfactorily as considered by NORBIT. Accordingly, NORBIT has decided to rescind the share purchase agreement and withdraw from the process. NORBIT will continue to explore value-accretive acquisitions through its defined criteria to accelerate growth beyond its organic revenue target of NOK 1.5 billion in 2024. For more information, please contact:Per Jørgen Weisethaunet, CEO, +47 959 62 915Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT NORBIT is a global provider of tailored technology...

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual MeetingHighly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses ≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia Study exceeded expectations for correction of hypoglycemia across multiple metrics, including hypoglycemia events and time in hypoglycemia Predictable and dose-dependent exposures with a clear dose-response Good safety and tolerability across all doses with no study discontinuations or adverse drug reactions Results are Phase 3 enabling and demonstrate the potential for RZ358 to be used as a monotherapy as well as a potential universal therapy for all forms of hyperinsulinism Company hosting Analyst and Investor Conference...

– Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC – – Reductions in mean annualized anti-VEGF injections ranged from 81% in all patients to 94% in those with NAbs

SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE). For each of the five weeks in the month of May, Exagen will focus on a different theme that, when combined, provides a holistic view of the work being done within the lupus community. These themes include:Diagnosis: highlighting the role and importance of an early and accurate diagnosis. Advocacy: sharing the stories of patient advocates, and their impact on the community. Community: shedding light on the regional and local efforts bringing people together. Research: providing insight into...

— Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up —— All Patients with Pain at Baseline Reported Zero Pain by Week 3 —— KPI-012 was Well-Tolerated with No Significant Safety Issues Observed —— On Track to Submit Investigational New Drug Application (IND) and Initiate Phase 2/3 Trial in 4Q 2022 — ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of...

New data highlights include: – Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH – Initial findings from research on comorbidities associated with adult growth hormone deficiency COPENHAGEN, Denmark, May 01, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will present clinical and research outcomes and host informational booths and events at four medical meetings during May. Topics will include new open-label extension data for children with growth hormone deficiency treated with TransCon hGH for 2.5 years; research findings showing comorbidities associated with adult growth hormone deficiency; and presentations of TransCon PTH Phase 2 patient-reported health, quality-of-life, and Week 84 data in adult...

In accordance with Section 32 of the Danish Capital Markets Act, GN Store Nord is required to publish the total number of voting rights and the size of the share capital in the company as per the end of a month during which changes have occurred. Referring to company announcement no. 8 of April 7, 2022, as per April 30, 2022, the share capital of GN Store Nord is nominally DKK 548,773,512 divided into shares of DKK 4 each, corresponding to 137,193,378 shares. The total voting rights in the company are 548,773,512. For further information, please contact: Investors and analystsHenriette WennickeVice President – Investor Relations & TreasuryTel: +45 45 75 03 33 or Rune SandagerDirector – Investor Relations & Treasury  Tel: +45 45 75 92 57 Press and the media Lars Otto Andersen-Lange Head of Media Relations & Corporate Public...

BEIJING, May 01, 2022 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that the Company delivered 4,167 Li ONEs in April 2022. Cumulative deliveries of Li ONE have reached 159,971 since the vehicle’s market debut in 2019. “The COVID-19 resurgence in the Yangtze Delta region continues to cause severe industry-wide disruptions in supply chain, logistics and production since late March. Our Changzhou manufacturing base is located in the center of the Yangtze Delta region, which is home to over 80% of our parts suppliers, especially in Shanghai and Kunshan. The COVID-19 resurgence in this area has incapacitated some suppliers in Shanghai and Kunshan. Some of them completely shut down production or delivery of their products, making...

NIO ET5 First NIO ET5 tooling trial builds rolled off the production lineNIO delivered 5,074 vehicles in April 2022 NIO delivered 30,842 vehicles year-to-date in 2022, increasing by 13.5% year-over-year Cumulative deliveries of vehicles as of April 30, 2022 reached 197,912SHANGHAI, China, May 01, 2022 (GLOBE NEWSWIRE) — NIO Inc. (“NIO” or the “Company”) (NYSE: NIO; HKEX: 9866), a pioneer and a leading company in the premium smart electric vehicle market, today announced its April 2022 delivery results. NIO delivered 5,074 vehicles in April 2022. The deliveries consisted of 4,381 premium smart electric SUVs, including 1,251 ES8s, 1,878 ES6s and 1,252 EC6s, and 693 ET7s, the Company’s flagship premium smart electric sedan. As of April 30, 2022, cumulative deliveries reached 197,912 vehicles. In late March and April 2022, the...